BNGO - Company ID 0001411690
Bionano Genomics, Inc. trades as BNGO. In its fiscal 2025 annual report the company posted revenue of $28.51M, down 7.4% from the prior year and net income of -$26.39M. This page tracks Bionano Genomics, Inc. through 603 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
With latest filings
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Over the last 8 fiscal years Bionano Genomics, Inc.'s revenue grew from $9.51M to $28.51M, a compound annual growth rate of 14.7%. Net profit margin expanded from -245.8% to -92.6% over the same period - every figure below comes from the company's audited annual filings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| Major company event | 8-K | 2026-05-28 |
| Insider trade | 4 | 2026-05-14 |
| Insider trade | 4 | 2026-05-14 |
| Insider trade | 4 | 2026-05-14 |
| Major company event | 8-K | 2026-05-14 |
| Insider trade | 4 | 2026-05-14 |
| Insider trade | 4 | 2026-05-14 |
| Quarterly report | 10-Q | 2026-05-13 |
The largest companies sharing Bionano Genomics, Inc.'s SEC industry classification (laboratory analytical instruments).
Bionano Genomics, Inc. reported revenue of $28.51M for fiscal year 2025, a decrease of 7.4% year over year.
In its latest fiscal year Bionano Genomics, Inc. reported a net loss of $26.39M.